A Phase 1b, Single Arm Study of CG0070 After Transurethral Resection in Patients With Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Latest Information Update: 07 Oct 2025
At a glance
- Drugs Cretostimogene grenadenorepvec (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
Most Recent Events
- 10 Sep 2025 Planned End Date changed from 1 Mar 2027 to 1 Sep 2027.
- 10 Sep 2025 Planned primary completion date changed from 1 Mar 2027 to 1 Sep 2027.
- 10 Sep 2025 Status changed from recruiting to active, no longer recruiting.